This agreement formalizes the collaboration between the two pharmaceutical laboratories specializing in research on natural substances. It involves bringing together two complementary areas of expertise. The Pierre Fabre Group will provide expertise in screening and research in oncology, while Nicholas Piramal India Limited (NPIL) will make available its natural products base, which will lead to the pharmacological characterization of new molecules.
This agreement forms a part of the strategy of Pierre Fabre Laboratories to reinforce their presence in India and open new avenues of collaboration in the field of oncology research, which represents 50% of the R&D investments of the Group.
Pierre Teillac, R&D Director of the Pierre Fabre Research Institute, said: “The two research teams of Pierre Fabre and NPIL have a common fundamental, a long tradition of working with natural substances. We are going to combine our know-how and our tools to discover together innovative molecules for the treatment of cancer.”